Antigen presentation by HLA-DR15+ MN from individual HIV-infected and uninfected subjects.

<p>MN (5×10⁴/well) were incubated with soluble HEL or peptide and T cell hybridoma (1×10⁵/well) for 24 hrs. Viremic HIV-infected individuals with VL>1000 are High VL and VL<1000 are Low VL. A. Control MN and soluble HEL, B. HIV+ MN and soluble HEL, C. Combined data on soluble HEL presentation, D. Control MN and peptide, E. HIV+ MN and peptide, F. Combined data on peptide presentation.</p

Antigen presentation by HLA-DR1+ MN from individual HIV-infected and uninfected subjects.

<p>In all four panels, MN (5×10⁴/well) were incubated with soluble antigen or peptide and T cell hybridoma (1×10⁵/well) for 24 hrs. Viremic HIV-infected individuals with VL>1000 are High VL and VL<1000 are Low VL. A. Control MN and soluble RT, B. HIV+ MN and soluble RT, C. Combined data on soluble RT presentation, D. Control MN and peptide, E. HIV+ MN and peptide, F. Combined data on peptide presentation.</p

Relationship between HLA-DR level and antigen presentation.

<p>Data from all 38 subjects in the study were normalized. The individual's ratio of presentation was calculated by dividing their IL-2 level for the middle concentration of RT, HEL or peptide by the mean IL-2 level from the control subjects at the same middle concentration of antigen or peptide. Open red diamonds are data from HIV-infected individuals and closed black diamonds for uninfected controls.</p

Characterization of T cell hybridoma clone 15HEL.

<p>MN (5×10⁴/well) were incubated with antigen (intact HEL for A and C, HEL peptides for B) and 15HEL (1×10⁵/well) for 24 hrs. Supernatants were harvested, and IL-2 measured by ELISA. A. Effect of anti-HLA-DR or isotype on response. B. Identification of HEL peptide epitope recognized by 15HEL. C. Effect of anti-CD80 and CD86 antibodies together (5 µg/ml of each) or isotype control (10 µg/ml) on responses. Results of A and C represent triplicate wells and error bars SEM.</p